Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00049561.xml
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(01): 082-083
DOI: 10.1055/s-0041-1731911
DOI: 10.1055/s-0041-1731911
Case Report
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Publication History
Article published online:
11 November 2021
© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Tsur N, Kogan Y, Avizov-Khodak E. et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J Transl Med 2019; 17 (01) 338
- 2 Burns MC, O'Donnell A, Puzanov I. Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016; 4 (08) 867-873
- 3 Diamantopoulos P, Gogas H. Melanoma immunotherapy dominates the field. Ann Transl Med 2016; 4 (14) 269
- 4 Robert C, Ribas A, Hamid O. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018; 36 (17) 1668-1674
- 5 Cancer Research Institute. Immunotherapy for Melanoma. Accessed August 20, 2020 at: https://www.cancerresearch.org/immunotherapy/cancer-types/melanoma